Bracing for the next wave in anticoagulation care
Setting the stage: Why we need “what’s next” in anticoagulation
Direct oral anticoagulants (DOACs) have been a genuine leap forward. It wasn’t long ago when regular INR checks and dietary restrictions were a daily part of life for anyone on warfarin. DOACs changed the rhythm: more predictable effects, fewer interactions, and a lighter monitoring load. But as with any major advance, new gaps appeared:
- Bleeding risk remains real for many.
- Reversal can be complicated, especially in emergencies.
- Special populations (think renal impairment, cancer, or unique body types) aren’t always well served.
- And we all know the headache of managing transitions for patients switching anticoagulant regimens.
That’s why so many eyes are now on the next generation of oral anticoagulants. Medicines that could bring us closer to the balance we’re after: safety, precision, and ease.
What’s in the pipeline: Key targets and mechanisms
Right now, Factor XIa (FXIa) inhibitors are leading the conversation. Here’s why: FXI sits further down the clotting cascade, so blocking it might lower clot risk without causing as much bleeding as our current options. Several oral FXIa inhibitors are in clinical trials, some already in Phase 2 and 3.
But that’s not all:
- Selective coagulation modulators: Researchers are also working on drugs that carefully target other steps in clot formation or break down clots more gently.
- Universal reversal agents: For example, ciraparantag (a so-called “universal antidote”) can rapidly reverse the effects of several anticoagulants in early studies.
- “Smart” anticoagulants: Imagine a pill that “switches off” when a bleeding risk is detected. It sounds like science fiction today, but work is quietly underway.
How it could shift guidelines and pharmacist roles
If you’re thinking this is just another round of “me-too” drugs, think again. The ripple effects could be big:
Bleeding risk recalibration
If new drugs really are safer, we may see guidelines expand who we treat. Patients we once considered “too risky” might finally get the protection they need.
New (and possibly less) monitoring
Just as DOACs let us ditch routine INR checks, the next wave could further reduce the need for traditional labs. But don’t get too comfortable since new drugs may require us to learn about novel markers, tests, or even genetic assays to individualize care.
Emergency protocols and reversal
Imagine not having to scramble for the “right” antidote. If broad-spectrum reversal agents like ciraparantag pan out, integrating them into emergency teams, EHR alerts, and pharmacy stockrooms will be essential.
Nuanced patient selection
Tomorrow’s anticoagulant landscape will be all about precision. We’ll need to weigh which agent really fits a patient’s risk profile, underlying conditions, and the likelihood of transitions.
Formulary and payer realities
Every advance comes with a price tag. These new medications will likely be costly at first, with insurers and health systems scrutinizing value. Pharmacies will play a key role in cost-benefit analysis, policy development, and patient advocacy.
What pharmacists should do now
If we wait until these drugs hit the shelves, we’ll be behind. Here’s what I recommend starting today:
- Stay current on clinical trials, especially for FXIa inhibitors and new reversal agents.
- Advocate for new decision support tools and protocols.
- Work with your lab and IT teams to set the groundwork for new testing or alert systems.
- Develop clear, accessible educational materials for patients and clinicians.
- Track outcomes (bleeding rates, thrombosis, medication switches) so you’re ready to demonstrate value.
Final thoughts: Refinement, not replacement
This next chapter isn’t about discarding what works, but about pushing for better: safer, more personalized, more responsive care. We’re moving from a one-size-fits-all model to one that meets patients where they are.
For pharmacists, this is an invitation to shift from managers to leaders. To be the ones who interpret the science, update the protocols, teach the teams, and ultimately help every patient get the safest, most effective care possible.
References
Ansell, J. (2021). Ciraparantag reverses the anticoagulant activity of direct oral anticoagulants: A review. PMC. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900496/
Gendron, N. (2024). Is there a role for the laboratory monitoring of new anticoagulants? Thrombosis Research, S0049-3848(24)00118-X. https://doi.org/10.1016/j.thromres.2024.01.003
Harrington, J., & Patel, M. R. (2022, June 17). The next wave of anticoagulation: Results of PACIFIC-AF. American College of Cardiology. Retrieved from https://www.acc.org/Latest-in-Cardiology/Articles/2022/06/17/11/54/The-Next-Wave-of-Anticoagulation
Koulas, I., et al. (2023). A review of FXIa inhibition as a novel target for anticoagulation. Journal of Clinical Investigation, 2023(XX), XX–XX. https://doi.org/10.1055/a-1984-7021
Leentjens, J. (2022). A short review of ciraparantag in perspective of the currently available anticoagulant reversal agents. Journal of Hemostasis and Thrombosis, 2022, XX–XX.
Mujer, M. T. P., et al. (2020). An update on the reversal of non-vitamin K antagonist oral anticoagulants. Journal of Thrombosis and Haemostasis, 2020(XX), XX–XX. https://doi.org/10.1155/2020/7636104
Sammut, M. A., et al. (2024). Factor XI and XIa inhibition: A new approach to anticoagulant therapy. British Journal of Cardiology. Retrieved from https://bjcardio.co.uk/2024/05/factor-xi-and-xia-inhibition-a-new-approach-to-anticoagulant-therapy/
Xia, Y., et al. (2023). Factor XIa inhibitors as a novel anticoagulation target: progress and perspectives. Pharmaceuticals, 16(6), 866. https://doi.org/10.3390/ph16060866
